Century Therapeutics
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | 5.2m | 2.2m | 7.3m | 9.8m |
% growth | - | - | - | - | (57 %) | 227 % | 34 % |
EBITDA | (18.6m) | (47.1m) | (94.5m) | (121m) | (99.8m) | - | - |
% EBITDA margin | - | - | - | (2333 %) | (4467 %) | - | - |
Profit | (245m) | (53.6m) | (95.8m) | (131m) | (137m) | - | - |
% profit margin | - | - | - | (2518 %) | (6115 %) | - | - |
R&D budget | 14.3m | 39.7m | 75.6m | 107m | 92.7m | - | - |
R&D % of revenue | - | - | - | 2061 % | 4148 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- |
| N/A | - |
$250m Valuation: $800m | Series A | ||
$160m Valuation: $1.3b -26.6x EV/LTM EBITDA | Series C | ||
N/A | N/A | IPO | |
* | $50.0m Valuation: $1.3b -13.2x EV/LTM EBITDA | Post IPO Equity | |
* | $60.0m | Private Placement VC | |
Total Funding | €427m |
Recent News about Century Therapeutics
EditCentury Therapeutics, Inc. is a pioneering biotechnology company focused on developing transformative allogeneic cell therapies. These therapies are designed to treat both hematological (blood-related) and solid tumor malignancies, addressing significant unmet medical needs in the healthcare sector. The company leverages a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells (iPSCs), advanced differentiation techniques to generate immune effector cells from iPSCs, and CRISPR-mediated precision gene editing.
Century Therapeutics operates primarily in the biotechnology and healthcare markets, serving patients with severe cancer conditions. The business model revolves around research and development (R&D) of innovative therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of successful therapies.
Keywords: allogeneic cell therapies, hematological malignancies, solid tumors, iPSCs, CRISPR, biotechnology, immune effector cells, cancer treatment, R&D, healthcare.